A Review of FDA’s Updated Guidance for Developing Drugs to Treat Early Alzheimer’s Disease

An overview of outcome measures and early diagnosis in new FDA guidance for Alzheimer's disease trials

Read more

Published in the Journal for Clinical Studies, this review highlights salient aspects of recent regulatory guidance that may impact developers of drugs to treat early Alzheimer’s disease.


Chief Development Officer
Vice President, Project Management, Neuroscience

Want to learn more about Worldwide Clinical Trials?